Helga Ellingsgaard1, Eleonora Seelig2,3, Katharina Timper2,4, Michael Coslovsky5, Line Soederlund6, Mark P Lyngbaek6, Nicolai J Wewer Albrechtsen7, Arno Schmidt-Trucksäss8, Henner Hanssen8, Walter O Frey9, Kristian Karstoft6, Bente K Pedersen6, Marianne Böni-Schnetzler10, Marc Y Donath2,10. 1. Centre of Inflammation and Metabolism (CIM)/ Centre for Physical Activity Research (CFAS), Rigshospitalet 7641, Blegdamsvej 9, DK-2100, Copenhagen, Denmark. Helga.Ellingsgaard@regionh.dk. 2. Clinic of Endocrinology, Diabetes and Metabolism University Hospital Basel, Basel, Switzerland. 3. University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. 4. Max Planck Institute for Metabolism Research Cologne, Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), University Hospital Cologne, Cologne, Germany. 5. Department of Clinical Research, CTU, University of Basel, University Hospital Basel, Basel, Switzerland. 6. Centre of Inflammation and Metabolism (CIM)/ Centre for Physical Activity Research (CFAS), Rigshospitalet 7641, Blegdamsvej 9, DK-2100, Copenhagen, Denmark. 7. Department of Clinical Biochemistry, Rigshospitalet University of Copenhagen, Copenhagen, Denmark. 8. Sports and Exercise Medicine, Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland. 9. Balgrist MoveMed, Swiss Olympic Medical Center, University Hospital Balgrist, Zurich, Switzerland. 10. Department Biomedicine, University of Basel, Basel, Switzerland.
Abstract
AIMS/HYPOTHESIS: IL-6 is a cytokine with various effects on metabolism. In mice, IL-6 improved beta cell function and glucose homeostasis via upregulation of glucagon-like peptide 1 (GLP-1), and IL-6 release from muscle during exercise potentiated this beneficial increase in GLP-1. This study aimed to identify whether exercise-induced IL-6 has a similar effect in humans. METHODS: In a multicentre, double-blind clinical trial, we randomly assigned patients with type 2 diabetes or obesity to intravenoustocilizumab (an IL-6 receptor antagonist) 8 mg/kg every 4 weeks, oral sitagliptin (a dipeptidyl peptidase-4 inhibitor) 100 mg daily or double placebos (a placebo saline infusion every 4 weeks and a placebo pill once daily) during a 12 week training intervention. The primary endpoints were the difference in change of active GLP-1 response to an acute exercise bout and change in the AUC for the concentration-time curve of active GLP-1 during mixed meal tolerance tests at baseline and after the training intervention. RESULTS:Nineteen patients were allocated to tocilizumab, 17 to sitagliptin and 16 to placebos. During the acute exercise bout active GLP-1 levels were 26% lower with tocilizumab (multiplicative effect: 0.74 [95% CI 0.56, 0.98], p = 0.034) and 53% higher with sitagliptin (1.53 [1.15, 2.03], p = 0.004) compared with placebo. After the 12 week training intervention, the active GLP-1 AUC with sitagliptin was about twofold that with placebo (2.03 [1.56, 2.62]; p < 0.001), while GLP-1 AUC values showed a small non-significant decrease of 13% at 4 weeks after the last tocilizumab infusion (0.87 [0.67, 1.12]; p = 0.261). CONCLUSIONS/ INTERPRETATION:IL-6 is implicated in the regulation of GLP-1 in humans. IL-6 receptor blockade lowered active GLP-1 levels in response to a meal and an acute exercise bout in a reversible manner, without lasting effects beyond IL-6 receptor blockade. TRIAL REGISTRATION: Clinicaltrials.gov NCT01073826. FUNDING: Danish National Research Foundation. Danish Council for Independent Research. Novo Nordisk Foundation. Danish Centre for Strategic Research in Type 2 Diabetes. European Foundation for the Study of Diabetes. Swiss National Research Foundation.
RCT Entities:
AIMS/HYPOTHESIS: IL-6 is a cytokine with various effects on metabolism. In mice, IL-6 improved beta cell function and glucose homeostasis via upregulation of glucagon-like peptide 1 (GLP-1), and IL-6 release from muscle during exercise potentiated this beneficial increase in GLP-1. This study aimed to identify whether exercise-induced IL-6 has a similar effect in humans. METHODS: In a multicentre, double-blind clinical trial, we randomly assigned patients with type 2 diabetes or obesity to intravenous tocilizumab (an IL-6 receptor antagonist) 8 mg/kg every 4 weeks, oral sitagliptin (a dipeptidyl peptidase-4 inhibitor) 100 mg daily or double placebos (a placebo saline infusion every 4 weeks and a placebo pill once daily) during a 12 week training intervention. The primary endpoints were the difference in change of active GLP-1 response to an acute exercise bout and change in the AUC for the concentration-time curve of active GLP-1 during mixed meal tolerance tests at baseline and after the training intervention. RESULTS: Nineteen patients were allocated to tocilizumab, 17 to sitagliptin and 16 to placebos. During the acute exercise bout active GLP-1 levels were 26% lower with tocilizumab (multiplicative effect: 0.74 [95% CI 0.56, 0.98], p = 0.034) and 53% higher with sitagliptin (1.53 [1.15, 2.03], p = 0.004) compared with placebo. After the 12 week training intervention, the active GLP-1 AUC with sitagliptin was about twofold that with placebo (2.03 [1.56, 2.62]; p < 0.001), while GLP-1 AUC values showed a small non-significant decrease of 13% at 4 weeks after the last tocilizumab infusion (0.87 [0.67, 1.12]; p = 0.261). CONCLUSIONS/ INTERPRETATION:IL-6 is implicated in the regulation of GLP-1 in humans. IL-6 receptor blockade lowered active GLP-1 levels in response to a meal and an acute exercise bout in a reversible manner, without lasting effects beyond IL-6 receptor blockade. TRIAL REGISTRATION: Clinicaltrials.gov NCT01073826. FUNDING: Danish National Research Foundation. Danish Council for Independent Research. Novo Nordisk Foundation. Danish Centre for Strategic Research in Type 2 Diabetes. European Foundation for the Study of Diabetes. Swiss National Research Foundation.
Authors: Helga Ellingsgaard; Irina Hauselmann; Beat Schuler; Abdella M Habib; Laurie L Baggio; Daniel T Meier; Elisabeth Eppler; Karim Bouzakri; Stephan Wueest; Yannick D Muller; Ann Maria Kruse Hansen; Manfred Reinecke; Daniel Konrad; Max Gassmann; Frank Reimann; Philippe A Halban; Jesper Gromada; Daniel J Drucker; Fiona M Gribble; Jan A Ehses; Marc Y Donath Journal: Nat Med Date: 2011-10-30 Impact factor: 53.440
Authors: X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard Journal: Diabetes Care Date: 1997-04 Impact factor: 19.112
Authors: Ralph A DeFronzo; John B Buse; Terri Kim; Colleen Burns; Sharon Skare; Alain Baron; Mark Fineman Journal: Diabetologia Date: 2016-05-23 Impact factor: 10.122
Authors: Sara E Stinson; Anna E Jonsson; Morten A V Lund; Christine Frithioff-Bøjsøe; Louise Aas Holm; Oluf Pedersen; Lars Ängquist; Thorkild I A Sørensen; Jens J Holst; Michael Christiansen; Jens-Christian Holm; Bolette Hartmann; Torben Hansen Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958
Authors: Mark P P Lyngbaek; Grit E Legaard; Sebastian L Bennetsen; Camilla S Feineis; Villads Rasmussen; Nana Moegelberg; Cecilie F Brinkløv; Anette B Nielsen; Katja S Kofoed; Carsten A Lauridsen; Caroline Ewertsen; Henrik E Poulsen; Robin Christensen; Gerrit Van Hall; Kristian Karstoft; Thomas P J Solomon; Helga Ellingsgaard; Thomas P Almdal; Bente K Pedersen; Mathias Ried-Larsen Journal: Trials Date: 2021-04-01 Impact factor: 2.279
Authors: Stephan Wueest; Eleonora Seelig; Katharina Timper; Mark P Lyngbaek; Kristian Karstoft; Marc Y Donath; Helga Ellingsgaard; Daniel Konrad Journal: Metabolites Date: 2021-01-29
Authors: Maria D Giraldez; David Carneros; Christoph Garbers; Stefan Rose-John; Matilde Bustos Journal: Nat Rev Gastroenterol Hepatol Date: 2021-07-01 Impact factor: 46.802